Related references
Note: Only part of the references are listed.Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
G. L. Goll et al.
JOURNAL OF INTERNAL MEDICINE (2019)
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
Bente Glintborg et al.
RMD OPEN (2019)
Health Care Spending in the United States and Other High-Income Countries
Irene Papanicolas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Till Uhlig et al.
RHEUMATOLOGY (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010
Anna-Birgitte Aga et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Biosimilars in rheumatology: the wind of change
Christian K. Schneider
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)